Key Takeaways Real-world results with weight-loss drugs aren’t as impressive as those in clinical trialsClinic patients ...

A clash is brewing between doctors and patients when it comes to treatment for sleep apnea in those with obesity, a new study ...

Researchers found that injectable GLP-1 receptor agonists for obesity tended to yield smaller reductions in weight in ...

Injectable GLP-1 drugs for obesity have been found to produce smaller weight loss in a real-world setting compared to ...

But patients would rather treat their sleep apnea with tirzepatide (Zepbound), a GLP-1 weight-loss drug, researchers found. "The results highlight a need for real-world comparative effectiveness ...

“The results highlight a need for real-world comparative effectiveness data of CPAP ... the U.S. Food and Drug Administration (FDA) approved Zepbound as the first drug to treat people with ...

“In real-world terms, that means many patients ... “We now have more than one highly effective option, and Zepbound seems to be leading the pack,” he said. An important implication, for ...

Weight-loss medications continue to grow in popularity as an anti-obesity tool — but are some more effective than others ... of tirzepatide (brand name Zepbound) and semaglutide (brand name ...

A new study published in the New England Journal of Medicine comparing Eli Lilly’s Zepbound to Novo Nordisk ... found that Zepbound is more effective for weight loss. The study was funded ...